home / stock / iphyf / iphyf quote
Last: | $2.20 |
---|---|
Change Percent: | 0.0% |
Open: | $0 |
Close: | $2.20 |
High: | $0 |
Low: | $0 |
Volume: | 1 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$2.2 | $0 | $2.2 | $0 | $0 | 1 | 05-20-2024 |
$2.2 | $2.2 | $2.2 | $2.2 | $2.2 | 100 | 05-08-2024 |
$2.2 | $2.2 | $2.2 | $2.2 | $2.2 | 10,000 | 05-07-2024 |
$2.13 | $2.13 | $2.13 | $2.13 | $2.13 | 2,000 | 05-03-2024 |
$2.65 | $2.43 | $2.65 | $2.65 | $2.43 | 300 | 04-02-2024 |
$2.58 | $2.39 | $2.58 | $2.65 | $2.39 | 800 | 03-29-2024 |
$2.58 | $2.39 | $2.58 | $2.65 | $2.39 | 800 | 03-28-2024 |
$2.3405 | $2.3405 | $2.3405 | $2.3405 | $2.3405 | 200 | 03-27-2024 |
$2.395 | $2.395 | $2.395 | $2.395 | $2.395 | 100 | 03-19-2024 |
$2.44 | $2.44 | $2.44 | $2.44 | $2.44 | 100 | 03-11-2024 |
$2.52 | $2.52 | $2.52 | $2.52 | $2.52 | 200 | 03-06-2024 |
$2.84 | $0 | $2.84 | $0 | $0 | 5 | 01-05-2024 |
$2.84 | $2.895 | $2.84 | $2.895 | $2.84 | 300 | 01-01-2024 |
$2.84 | $2.895 | $2.84 | $2.895 | $2.84 | 300 | 12-29-2023 |
$2.65 | $2.65 | $2.65 | $2.65 | $2.65 | 200 | 12-27-2023 |
$2.756 | $2.66 | $2.756 | $2.756 | $2.66 | 1,200 | 12-25-2023 |
$2.756 | $2.66 | $2.756 | $2.756 | $2.66 | 1,200 | 12-22-2023 |
$2.7 | $2.77 | $2.7 | $2.77 | $2.7 | 625 | 12-21-2023 |
$2.55 | $2.594 | $2.55 | $2.594 | $2.55 | 600 | 12-11-2023 |
$2.37 | $2.37 | $2.37 | $2.37 | $2.37 | 100 | 12-07-2023 |
News, Short Squeeze, Breakout and More Instantly...
Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that in an abstract published on 14 May 2024 for the European Hematology Association 2024 Congress on SAR443579/IPH6101, submitted by Sanof...
Two abstracts on SAR443579 (IPH6101), ANKET ® platform lead asset, a trifunctional anti-CD123 NKp46xCD16 NK cell engager under development by partner Sanofi in blood cancer Two abstracts on IPH6501, Innate’s second generation ANKET ® for the treatment of relap...
First preclinical data set for IPH45, a pre-IND anti-Nectin-4 Antibody Drug Conjugate, presented as an oral presentation at AACR 2024 Progression of Sanofi-developed NK Cell Engager SAR443579/IPH6101 to Phase 2 in blood cancers Five ASCO Annual Meeting 2024 abstracts: ...